Nature

Oncogenesis articles from across Nature Portfolio

Oncogenesis is the process through which healthy cells become transformed into cancer cells. It is characterized by a series of genetic and cellular changes, including oncogene activation, that lead the cell to divide in an uncontrolled manner.

Latest Research and Reviews

Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures

Paediatric high-grade gliomas with MYCN amplification (HGG-MYCN) are rare and highly aggressive. Here, the authors generate a mouse model for HGG-MYCN that can recapitulate the histological and molecular profiles of the human tumours, and perform high-throughput drug screening to identify potential treatment options.
- Melanie Schoof
- Shweta Godbole
- Ulrich Schüller
ResearchOpen Access24 Nov 2023 Nature Communications
Volume: 14, P: 7717
Differential spatial distribution of HNF4α isoforms during dysplastic progression of intraductal papillary mucinous neoplasms of the pancreas
- Jahg Wong
- Vincent Q. Trinh
- Marcus Tan
ResearchOpen Access16 Nov 2023 Scientific Reports
Volume: 13, P: 20088
Nuclear transport proteins: structure, function, and disease relevance
- Yang Yang
- Lu Guo
- Qingxiang Sun
ReviewsOpen Access10 Nov 2023 Signal Transduction and Targeted Therapy
Volume: 8, P: 425
USP4 promotes the proliferation, migration, and invasion of esophageal squamous cell carcinoma by targeting TAK1
- Hongdian Zhang
- Youming Han
- Zhentao Yu
ResearchOpen Access10 Nov 2023 Cell Death & Disease
Volume: 14, P: 730
FOXO family isoforms
- Bruno F. Santos
- Inês Grenho
- Wolfgang Link
ReviewsOpen Access27 Oct 2023 Cell Death & Disease
Volume: 14, P: 702
Intradural extramedullary metastasis of oncocytic carcinoma of the parotid gland: A first case report and review of the literature
- Gwenaelle Schackis
- Tuan Le Van
- Philibert Alixant
Research05 Oct 2023 Spinal Cord Series and Cases
Volume: 9, P: 49

All Research & Reviews

News and Comment

Ectodysplasin A2 receptor-NF-κB-inducing kinase axis: a new player in muscle wasting to cancer cachexia
- Janusz von Renesse
- Peter Mirtschink
Research HighlightsOpen Access09 Oct 2023 Signal Transduction and Targeted Therapy
Volume: 8, P: 383
Emerging cancer risks in BRCA2 pathogenic germline variant carriers
- Patrick R. Benusiglio
- Antoine Dardenne
- Jacques Cadranel
Comments & Opinion28 Sept 2023 European Journal of Human Genetics
Volume: 31, P: 1355-1356
Multiomics of three hematological malignancies in a patient reveal their origin from clonal hematopoietic stem cells
- Sylvain Mayeur
- Anne Molitor
- Alina Nicolae
CorrespondenceOpen Access09 Aug 2023 Blood Cancer Journal
Volume: 13, P: 118
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
- Paola Guglielmelli
- Chiara Maccari
- Alessandro M. Vannucchi
CorrespondenceOpen Access30 Jan 2023 Blood Cancer Journal
Volume: 13, P: 21
Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia
- Jeffrey D. Mandell
- J. Nick Fisk
- Jeffrey P. Townsend
CorrespondenceOpen Access11 Nov 2022 Leukemia
Volume: 36, P: 2931-2933
The KRAS^G12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis

The identification of KRAS^G12C inhibitors has reignited interest in targeting RAS proteins. This work describes the discovery of the KRAS^G12D-specific inhibitor MRTX1133 and demonstrates the feasibility of potently and selectively targeting this oncogenic variant. MRTX1133 treatment markedly inhibited KRAS-dependent signaling and induced tumor regression in xenograft models harboring the KRAS^G12D mutation.

News & Views07 Oct 2022 Nature Medicine
Volume: 28, P: 2017-2018

All News & Comment

Search

Advanced search

Quick links